The historic rise of Viagra has firmly established as a benchmark of pharmaceutical success, however its legacy within the broader industry now raises questions about future gains. Copycat versions are undercutting market share, causing worries that investing in companies heavily reliant to Viagra's previous position could be a problematic decision